Axa
LRMR icon

Axa’s Larimar Therapeutics LRMR Stock Holding History

Axa’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-19,750
Closed -$1.49M – 1368
2015
Q4 		$1.49M Sell
19,750
-2,045
-9% -$328K 0.01% 836
2015
Q3 		$8.36M Buy
+21,795
New +$9.83M 0.03% 427

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Axa's LRMR Position: Q1 2016 in Review

Axa sold out of Larimar Therapeutics (LRMR) in Q1 2016, closing a stake of 19,750 shares — an estimated $1.49M sold.

Axa first reported a position in LRMR in Q3 2015 and held it in 2 quarters. The position peaked at $8.36M in Q3 2015. 80 funds tracked by Wall St. Rank hold LRMR as of Q1 2016.

  • Axa reported no remaining Larimar Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Axa sold 19,750 Larimar Therapeutics shares in Q1 2016, an estimated $1.49M.
  • Axa first reported a position in Larimar Therapeutics in Q3 2015 and held it in 2 quarters.
  • Axa's Larimar Therapeutics position peaked at $8.36M in Q3 2015.
  • 80 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2016.

Based on Axa's 13F filing for Q1 2016, filed 13 May 2016.